We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
- Authors
Shulman, Lawrence N; Cirrincione, Constance T; Berry, Donald A; Becker, Heather P; Perez, Edith A; O'Regan, Ruth; Martino, Silvana; Atkins, James N; Mayer, Erica; Schneider, Charles J; Kimmick, Gretchen; Norton, Larry; Muss, Hyman; Winer, Eric P; Hudis, Clifford
- Abstract
The ideal duration of adjuvant chemotherapy for patients with lower risk primary breast cancer is not known. Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial design to define whether six cycles of a chemotherapy regimen are superior to four cycles. We also sought to determine whether paclitaxel (T) is as efficacious as doxorubicin/cyclophosphamide (AC), but with reduced toxicity.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 33, p4071
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.40.6405